60 Degrees Pharmaceuticals develops and commercializes medicines for vector-borne disease, with news centered on ARAKODA® (tafenoquine), its FDA-approved malaria prophylaxis product, and related tafenoquine development work. Company updates also cover access and marketing partnerships for ARAKODA, annual product revenue reporting, capital actions, and Nasdaq listing-related corporate measures.
Recurring development news includes studies involving tafenoquine for babesiosis, where the drug is not FDA-approved, and regulatory and licensing activity tied to Australian Chestnut Extract, castanospermine, celgosivir-related science, and non-prescription botanical product plans.
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
FAQ
What is the current stock price of 60 Degrees Pharmaceuticals Warrant (SXTPW)?
The current stock price of 60 Degrees Pharmaceuticals Warrant (SXTPW) is $0.032449 as of September 25, 2026.